BUDGET IMPACT ANALYSIS OF APREMILAST ON MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：0
|
作者：
Vanaclocha, F. [1 ]
Carrascosa, J. M. [2 ]
Caloto, T. [3 ]
Elias, I [4 ]
Echave, M. [4 ]
Tencer, T. [5 ]
机构：
[1] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[2] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[3] Celgene Corp, Dept Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.559
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS35
引用
收藏
页码：A421 / A421
页数：1
相关论文
共 50 条
  • [21] A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
    Chiricozzi, Andrea
    Caposiena, Dante
    Garofalo, Virginia
    Cannizzaro, Maria Vittoria
    Chimenti, Sergio
    Saraceno, Rosita
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (03) : 237 - 249
  • [22] Apremilast and Systemic Retinoid Combination Treatment for Moderate to Severe Palmoplantar Psoriasis
    Czarnowicki, Tali
    Rosendorff, B. Peter
    Lebwohl, Mark G.
    CUTIS, 2020, 106 (01): : E15 - E17
  • [23] Apremilast in the therapy of moderate to severe chronic plaque psoriasis and special locations
    Fernandez, Alvaro Barranquero
    Perez, Jorge Alonso Suarez
    Acosta, Enrique Herrera
    Fernandez, Maria Victoria Mendiola
    Ceballos, Enrique Herrera
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB46 - AB46
  • [24] Economic evaluation of apremilast in the treatment of moderate to severe psoriasis in the United States
    Tencer, Tom
    Clancy, Zoe
    Damera, Vidya
    Zhang, Frank
    Cure, Sandrine
    Feldman, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB97 - AB97
  • [25] EFFICACY OF TILDRAKIZUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS WITH PRIOR EXPOSURE TO APREMILAST
    Gordon, Kenneth
    Reich, Kristian
    Pariser, David
    Menter, Alan
    Tyring, Stephen
    Sofen, Howard
    Rozzo, Stephen
    Parno, Jeffrey
    Li, Qing
    La Rosa, Carmen
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 29 - 30
  • [26] Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis
    Bianchi, Luca
    Del Duca, Ester
    Romanelli, Marco
    Saraceno, Rosita
    Chimenti, Sergio
    Chiricozzi, Andrea
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1121 - 1128
  • [27] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
  • [28] Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study
    Ighani, Arvin
    Georgakopoulos, Jorge R.
    Zhou, Linda L.
    Walsh, Scott
    Shear, Neil
    Yeung, Jensen
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2018, 22 (03) : 290 - 296
  • [29] COST-EFFECTIVENESS OF APREMILAST IN MODERATE-TO-SEVERE PSORIASIS IN CANADA
    Cawston, H.
    Damera, V
    Ektare, V
    Shear, N. H.
    Tencer, T.
    Liu, F. F.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [30] Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
    Papp, Kim
    Cather, Jennifer C.
    Rosoph, Les
    Sofen, Howard
    Langley, Richard G.
    Matheson, Robert T.
    Hu, ChiaChi
    Day, Robert M.
    LANCET, 2012, 380 (9843) : 738 - 746
12345